Photo of Kenneth L. Kehl,  MD, MPH

Kenneth L. Kehl, MD, MPH

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute

Kenneth L. Kehl, MD, MPH

Dana-Farber Cancer Institute

EDUCATIONAL TITLES

  • Instructor, Medicine, Harvard Medical School
  • Physician, Medical Oncology, Dana-Farber Cancer Institute

DF/HCC PROGRAM AFFILIATION

Research Abstract

I am an Instructor in Medicine at Harvard Medical School and Physician at Dana-Farber Cancer Institute, where I conduct research in the Division of Population Sciences and provide clinical care for patients with lung cancer in the Thoracic Oncology Program. My primary interest is in improving outcomes for patients with lung cancer on a population basis by identifying ways to optimize the implementation of scientific and clinical innovation. My specific goal is to develop a research program around applying modern analytic techniques to electronic health records (EHR) data to more readily use such information to improve care. One key challenge in oncology is that most adults with cancer do not participate in clinical trials, such that understanding the impact of innovation on a population basis requires analysis of ‘real-world’ data sources that were not originally intended for research purposes. The EHR could constitute an important source of such data, but to date, applying the EHR for this purpose has been limited by the fact that key clinical outcomes, even including whether cancer improves or worsens after a given treatment, are generally recorded only in unstructured free text reports. Structuring these data has therefore traditionally required manual medical records review, which is a resource-intensive, error-prone process at scale. I am therefore developing machine learning techniques for abstracting outcomes data from the EHR. Additionally, my work includes the development of techniques for understanding population-level treatment patterns, comparative effectiveness, and the impact of policy shifts using insurance claims data at scale.

Publications

Powered by Harvard Catalyst
  • Kehl KL, Hassett MJ, Schrag D. Patterns of care for older patients with stage IV non-small cell lung cancer in the immunotherapy era. Cancer Med 2020; 9:2019-2029. PubMed
  • Kehl KL, Keating NL, Giordano SH, Schrag D. Insurance Networks and Access to Affordable Cancer Care. J Clin Oncol 2019. PubMed
  • Mendoza TR, Kehl KL, Bamidele O, Williams LA, Shi Q, Cleeland CS, Simon G. Assessment of baseline symptom burden in treatment-naïve patients with lung cancer: an observational study. Support Care Cancer 2019; 27:3439-3447. PubMed
  • Kehl KL, Elmarakeby H, Nishino M, Van Allen EM, Lepisto EM, Hassett MJ, Johnson BE, Schrag D. Assessment of Deep Natural Language Processing in Ascertaining Oncologic Outcomes From Radiology Reports. JAMA Oncol 2019. PubMed
  • Kehl KL, Yang S, Awad MM, Palmer N, Kohane IS, Schrag D. Pre-existing autoimmune disease and the risk of immune-related adverse events among patients receiving checkpoint inhibitors for cancer. Cancer Immunol Immunother 2019. PubMed
  • Kehl KL, Lathan CS, Johnson BE, Schrag D. Race, Poverty, and Initial Implementation of Precision Medicine for Lung Cancer. Journal of the National Cancer Institute 2018. PubMed
  • Kehl KL, Niu J, Chavez-MacGregor M, Giordano SH. Hospitalization by cytotoxic chemotherapy regimen among older women with stage IV breast cancer. Cancer 2019; 124:4685-4691. PubMed
  • Kehl KL, Fullmer CP, Fu S, George GC, Hess KR, Janku F, Karp DD, Kato S, Kizer CK, Kurzrock R, Naing A, Pant S, Piha-Paul SA, Subbiah V, Tsimberidou AM, Hong DS. Insurance Clearance for Early-Phase Oncology Clinical Trials Following the Affordable Care Act. Clin Cancer Res 2019. PubMed
  • Kehl KL, Liao KP, Krause TM, Giordano SH. Access to Accredited Cancer Hospitals Within Federal Exchange Plans Under the Affordable Care Act. J Clin Oncol 2018; 35:645-651. PubMed
  • Shen C, Kehl KL, Zhao B, Simon GR, Zhou S, Giordano SH. Utilization Patterns and Trends in Epidermal Growth Factor Receptor (EGFR) Mutation Testing Among Patients With Newly Diagnosed Metastatic Lung Cancer. Clin Lung Cancer 2018; 18:e233-e241. PubMed
  • Kehl KL, Shen C, Litton JK, Arun B, Giordano SH. Rates of BRCA1/2 mutation testing among young survivors of breast cancer. Breast Cancer Res Treat 2018; 155:165-73. PubMed
  • Kehl KL, Landrum MB, Kahn KL, Gray SW, Chen AB, Keating NL. Tumor board participation among physicians caring for patients with lung or colorectal cancer. J Oncol Pract 2015; 11:e267-78. PubMed
  • Kehl KL, Lamont EB, McNeil BJ, Bozeman SR, Kelley MJ, Keating NL. Comparing a medical records-based and a claims-based index for measuring comorbidity in patients with lung or colon cancer. 2015. PubMed
  • Kehl KL, Landrum MB, Arora NK, Ganz PA, van Ryn M, Mack JW, Keating NL. Association of Actual and Preferred Decision Roles With Patient-Reported Quality of Care: Shared Decision Making in Cancer Care. JAMA Oncol 2015; 1:50-8. PubMed
  • Kehl KL, Gray SW, Kim B, Kahn KL, Haggstrom D, Roudier M, Keating NL. Oncologists' experiences with drug shortages. J Oncol Pract 2015; 11:e154-62. PubMed
  • Kehl KL, Arora NK, Schrag D, Ayanian JZ, Clauser SB, Klabunde CN, Kahn KL, Fletcher RH, Keating NL. Discussions about clinical trials among patients with newly diagnosed lung and colorectal cancer. Journal of the National Cancer Institute 2014. PubMed
Hide